Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study

The U.S. Food and Drug Administration Adverse Event Reporting System and the World Health Organization's VigiBase databases were analyzed to clarify the differences in adverse events between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma. Results found that the reported numbers of immune-related AEs, including myocarditis, colitis, and hepatitis, were significantly higher with NIVO-IPI, but the reported numbers of other AEs, including gastrointestinal disorders and skin and subcutaneous tissue disorders were higher with NIVO-CABO.